series-a
Stage
2
Investors
About
Euthymics develops novel medications targeting central nervous system disorders, specifically Major Depressive Disorder (MDD) and Attention Deficit/Hyperactivity Disorder (ADHD).
Explore Euthymics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.